Xcout IntelMonte Rosa Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Monte Rosa Therapeutics, Inc. among biotech companies — ranked by similarity to what Monte Rosa Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Monte Rosa Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Monte Rosa Therapeutics, Inc. at a glance
Monte Rosa Therapeutics, Inc. is a biotech company headquartered in Boston, United States. It is publicly listed (GLUE) with a market capitalisation of $878.7M. Xcout tracks 23 named people at Monte Rosa Therapeutics, Inc., including Markus Warmuth (President, Chief Executive Officer & Director).
Monte Rosa Therapeutics, Inc. leadership
- Markus WarmuthPresident, Chief Executive Officer & Director
- Christine SiuChief Operating Officer in Residence, BridgeBio
- Jennifer ChampouxChief Operating Officer
- Magnus WalterChief Technology Officer
- Magnus Walter DPHILChief Technology Officer
- Filip JankuChief Medical Officer
17 more named people on record for Monte Rosa Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Monte Rosa Therapeutics, Inc. funding rounds before its IPO
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $48M | 13 named | |
| — | $32.5M | 14 named |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Monte Rosa Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Monte Rosa Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Similar biotech company
Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.
Similar biotech company
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Biotechnology
Great Bay Bio is a biotech company headquartered in HKSTP that drives drug development using cutting-edge technologies such as AI and big data mining.
Biotechnology
Superluminal Medicines is a generative biology and chemistry company headquartered in Boston, Massachusetts, focused on drug discovery and development.
Similar biotech company
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Similar biotech company
Metaphore Biotechnologies, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, operating as part of Flagship Pioneering. The company focuses on therapeutic design, leveraging AI and machine learning technologies for drug discovery and development.
Similar biotech company
Relation Therapeutics Inc. is an active for-profit biotechnology company founded in 2019 that focuses on therapeutic development.
Biotechnology
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Biotechnology
Tessellate Bio is a biotechnology company that develops precision oncology medicines by exploring synthetic lethal interactions beyond homologous recombination deficiency. The company integrates biomarker discovery and companion diagnostics into its research programs to create first-in-class treatments for hard-to-treat cancers.
Similar biotech company
Frontier Medicines, Corp. is a precision medicine company focusing on drug development with offices in locations including South San Francisco, California, and Boston.
Biotechnology
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Monte Rosa Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Monte Rosa Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →